SCHEMBL5886389

SCHEMBL5886389

NS(=O)(=O)c1ccc2c(ccc3nc4cccc(C(=O)O)c4nc32)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
CA1 P00915 8/20 0.39
CA2 P00918 8/20 0.39
CA9 Q16790 4/20 0.39
CA12 O43570 3/20 0.39
GLO1 Q04760 1/20 0.39
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886246 0.88 ALDH1A1 (0.51) ALDH1A1LMNATDP1MEN1KMT2A
SCHEMBL5886274 0.84 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL5886269 0.84 ALDH1A1 (0.48) ALDH1A1LMNAMEN1MAPTKMT2A
SCHEMBL5886283 0.83 ALDH1A1 (0.55) ALDH1A1TDP1MEN1MAPTKMT2A
SCHEMBL5886363 0.82 ALDH1A1 (0.56) ALDH1A1LMNATDP1MEN1MAPT
SCHEMBL5886412 0.80 ALDH1A1 (0.48) ALDH1A1LMNAMEN1MAPTKMT2A
SCHEMBL5886278 0.80 ALDH1A1 (0.54) ALDH1A1MAPTKMT2ACA1CA2
SCHEMBL5886494 0.79 ALDH1A1 (0.50) ALDH1A1TDP1MAPTKMT2APOLB
SCHEMBL5886390 0.78 ALDH1A1 (0.68) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL5886502 0.78 KDM4E (0.52) ALDH1A1LMNAMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US claimed
EP-1240148-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II Xenova Limited (GB) 2002-09-18 EP claimed
WO-2001046157-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II XENOVA LIMITED (GB) 2001-06-28 WO claimed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A ALDH1A1 3766/4885LMNA 3298/4885TDP1 4765/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B ALDH1A1 2334/4885LMNA 1336/4885TDP1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.